Compare LINC & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINC | IVA |
|---|---|---|
| Founded | 1946 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 813.3M | 796.1M |
| IPO Year | 2005 | 2020 |
| Metric | LINC | IVA |
|---|---|---|
| Price | $22.29 | $3.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $45.00 | $16.20 |
| AVG Volume (30 Days) | 694.3K | ★ 1.4M |
| Earning Date | 05-11-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $261,853,000.00 | N/A |
| Revenue This Year | $15.16 | N/A |
| Revenue Next Year | $9.02 | $751.20 |
| P/E Ratio | $119.40 | ★ N/A |
| Revenue Growth | ★ 32.98 | N/A |
| 52 Week Low | $17.29 | $3.11 |
| 52 Week High | $56.34 | $7.98 |
| Indicator | LINC | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 23.57 | 26.41 |
| Support Level | N/A | $3.35 |
| Resistance Level | $25.77 | $4.78 |
| Average True Range (ATR) | 1.15 | 0.24 |
| MACD | 0.32 | -0.09 |
| Stochastic Oscillator | 9.91 | 15.93 |
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include: Campus Operations and Transitional. The majority of the revenue is generated from the Campus Operations segment, which includes all campuses that are continuing in operation and contribute to the company's core operations and performance.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.